This study, published in Frontiers in Immunology, provides reassuring evidence that inactivated SARS-CoV-2 vaccines are generally safe for patients with Myasthenia Gravis (MG). While approximately 10% of patients reported some symptom worsening after vaccination, the majority of these cases were mild and transient, with recent disease instability (a flare-up within the previous six months) identified as the primary risk factor.
TL;DR
Inactivated SARS-CoV-2 vaccines are safe for most stable Myasthenia Gravis (MG) patients, with only 0.9% of participants requiring treatment escalation due to post-vaccination worsening. The study identifies a "six-month stability window" as a crucial predictor, where patients with recent aggravations are significantly more likely to experience a temporary increase in symptoms.
What Problem Does This Paper Address?
Myasthenia Gravis (MG) is a chronic autoimmune neuromuscular disease characterized by muscle weakness. Because vaccines work by stimulating the immune system, patients with autoimmune disorders often fear that vaccination might trigger a "flare" or worsening of their condition.
During the COVID-19 pandemic, this led to significant vaccine hesitancy among the MG community. While several studies had looked at mRNA vaccines (like Pfizer or Moderna), there was less data available regarding the safety of inactivated vaccines (such as Sinopharm or Sinovac), which were the primary options in many parts of the world, including China. This paper aims to quantify the risk of worsening and identify which clinical factors make a patient more "prone" to a post-vaccination flare.
Methods
The researchers conducted a retrospective, survey-based study involving 107 MG patients from two major neurological centers in North China.
- Data Collection: Patients were screened via a structured questionnaire (delivered through WeChat, telephone, or face-to-face) to report any "worsening" within 28 days of each vaccine dose.
- Defining Worsening: Worsening was defined as the emergence of new symptoms or the aggravation of existing ones in specific muscle groups (e.g., ocular, facial, bulbar).
- Severity Metric: Patients rated their overall severity on a scale of 0–100% (where 100% is "normal").
- Statistical Analysis: The team used multivariate logistic regression to determine which baseline factors—such as age, gender, antibody status, or disease duration—independently predicted a higher risk of worsening.
Datasets
The study utilized a specialized patient registry from:
- Qilu Hospital (Qingdao), Shandong University.
- Xuanwu Hospital, Capital Medical University (Beijing).
The final cohort consisted of 107 patients, 105 of whom received homologous inactivated vaccines.
Key Insights and Ideas
- The "Six-Month Rule": The most significant finding was that the interval since the last disease aggravation was the only independent predictor of worsening. Patients who had experienced a flare-up within 6 months prior to their first dose were 8.62 times more likely to report worsening after the vaccine.
- Subjective vs. Objective Worsening: While 10.3% of patients felt worse, only one patient (0.9%) actually required an escalation in immunosuppressive therapy. This suggests that most post-vaccination "worsening" is mild and does not represent a fundamental loss of disease control.
- Stability Over Severity: Interestingly, factors like the specific type of antibody (AChR vs. MuSK) or the presence of a thymoma did not significantly correlate with worsening. The current stability of the disease mattered more than the historical severity of the disease.
- Confounding Factors: In several cases where patients reported worsening, other "precipitating factors" were present, such as concurrent respiratory infections or extreme fatigue, suggesting the vaccine may not always be the sole culprit.
Key Results
- Incidence: 11 out of 107 patients (10.3%) reported worsening.
- Timing: Worsening was split almost evenly between the first dose (5.6%) and the second dose (6.2%). No patients reported worsening after a third (booster) dose.
- Clinical Impact: 8 patients had mild/moderate worsening; 3 had severe worsening. Only 1 patient required a change in medication (Tacrolimus and Prednisone).
- Regression Data: The interval since last aggravation $\leq$ 6 months was the standout risk factor ($P = 0.01, OR = 8.62, 95\% CI: 1.93–38.46$).
Limitations and Future Work
The authors acknowledge several limitations:
- Selection Bias: The study likely included "milder" patients, as those with very severe or unstable MG may have been advised by their doctors to avoid vaccination entirely.
- Sample Size: With only 107 patients, the study may lack the statistical power to detect very rare adverse events.
- Recall Bias: Because the study was retrospective and survey-based, it relied on patients' memories of their symptoms.
- Future Directions: The authors suggest that future research should include larger, prospective cohorts and perhaps compare the safety profiles of different vaccine platforms (inactivated vs. mRNA vs. viral vector) within the same autoimmune population.
Summary updated